ROCK1 Is Associated with Alzheimer’s Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic Aβ Clearance

Yong-Bo Hu†, Yang Zou††, Yue Huang‡, Yong-Fang Zhang§, Guinevere F. Lourenco‡, Sheng-Di Chen†, Glenda M. Halliday‡‡, Gang Wang†* and Ru-Jing Ren††*

† Department of Neurology and Neuroscience Institute, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, ‡ Neuroscience Research Australia and Faculty of Medicine, University of New South Wales (UNSW), Sydney, NSW, Australia, § Research Laboratory of Cell Regulation, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Alzheimer’s disease (AD) is the most prevalent form of late-life dementia in the population, characterized by amyloid plaque formation and increased tau deposition, which is modulated by Rho-associated coiled-coil kinase 1 (ROCK1). In this study, we further analyze whether ROCK1 regulates the metabolism of amyloid precursor protein (APP). We show that ROCK1 is colocalized with mature amyloid-β (Aβ) plaques in patients with AD, in that ROCK1 enhances the amyloidogenic pathway, and that ROCK1 mediated autophagy enhances the intracellular buildup of Aβ in a cell model of AD (confirmed by increased ROCK1 and decreased Beclin 1 protein levels, with neuronal autophagosome accumulation in prefrontal cortex of AD APP/PS1 mouse model). In vitro over-expression of ROCK1 leads to a decrease in Aβ secretion and an increase in the expression of autophagy-related molecules. ROCK1 interacts with Beclin1, an autophagy initiator, and enhances the intracellular accumulation of Aβ. Reciprocally, overexpression of APP/Aβ promotes ROCK1 expression. Our data suggest ROCK1 participates in regulating Aβ secretion, APP shedding and autophagosome accumulation, and that ROCK1, rather than other kinases, is more likely to be a targetable enzyme for AD therapy.

Keywords: Alzheimer’s disease, ROCK1, autophagy, Aβ, Beclin1

INTRODUCTION

Alzheimer’s disease (AD) is the leading cause of dementia, characterized by the accumulation of extracellular and vascular amyloid in the brain. Amyloid plaques are composed of amyloid-β (Aβ) peptides, and they are derived from the sequential cleavage of the amyloid precursor protein (APP) by a set of proteases. The cleavage of APP occurs through two different pathways:

**Abbreviations:** AD, Alzheimer’s disease; APP, amyloid precursor protein; Aβ, amyloid-β; ColIP, co-immunoprecipitation; PtdIns3KC3, phosphatidylinositol 3-kinase class III; ROCK1, Rho-associated coiled-coil kinase 1; 3-MA, 3-methyladenine.
a non-amyloidogenic pathway mediated by \( \alpha \)-secretase and an amyloidogenic pathway mediated by \( \beta \)-secretase (Tang, 2005). \( \alpha \)-Secretase is a metalloprotease and disintegrin enzyme that cleaves within the \( \beta \) sequence to generate a secreted APP fragment (sAPP\( \alpha \)). sAPP\( \alpha \) has neurotrophic properties and promotes neurite outgrowth modulating the efficacy of synaptic neurotransmission (Ma et al., 2009). Conversely, APP cleavage by \( \beta \)-secretase occurs at the N-terminus with the C-terminal APP fragment subsequently cleaved by \( \gamma \)-secretase leading to the production of \( \beta \)-A\( \beta \) peptides.

Rho-associated coiled-coil kinases (ROCKs) are Ser/Thr kinases and the first identified effectors of Rho GTPase. They are involved in several aspects of cell behavior, such as cell motility, cell proliferation and apoptosis (Chang et al., 2006; Yang et al., 2013; Loirand, 2015; Swanger et al., 2015). Research indicates that ROCKs are potential therapeutic targets for \( \beta \)-A\( \beta \) metabolism modulation (Weggen et al., 2001; Jacobs et al., 2006; Salminen et al., 2008). Two constitutively-expressed ROCK enzymes have been identified—ROCK1 and ROCK2 that share 92% homology in their kinase domain and differ most in their regulatory domains and subcellular localization (Ishizaki et al., 1997; Shi et al., 2013; Chong et al., 2016). Recent studies show that ROCK1 modulates the shedding of the \( \alpha \)-secretase-cleaved soluble APP ectodomain (sAPP\( \alpha \)) from cultured cells, and that ROCK1 deletion reduces the levels of \( \beta \)-A\( \beta \) (Herskowitz et al., 2013; Henderson et al., 2016). The buildup of internal \( \beta \)-A\( \beta \) rather than its external deposition is associated with neuronal loss in APP/PS1 knock-in mice suggesting externalization of cellular \( \beta \)-A\( \beta \) is protective (Christensen et al., 2008). However, the mechanism by which ROCK1 externalizes \( \beta \)-A\( \beta \) or regulates \( \beta \)-A\( \beta \) production remains to be determined.

In AD, autophagy directly affects the secretion of \( \beta \)-A\( \beta \) and amyloid plaque formation (Nilsson et al., 2013), and long-term rapamycin treatment reduces \( \beta \)-A\( \beta \) plaque load by the induction of autophagy in an AD mouse model (Nilsson et al., 2013). The pivotal role for autophagy in the clearance of aggregate-prone proteins also manifests with an accumulation of autophagic vacuoles (autophagosomes and autolysosomes) in several neurodegenerative diseases (Zhang et al., 2016). Beclin1-mediated autophagy is the major cellular pathway for degradation of aggregated proteins and is required for the formation of double-membrane vesicles, cytoplasmic organelles called an autophagosome (McLeland et al., 2011). This dynamic process involves autophagosome formation, autophagosome-lysosome fusion and the degradation of autophagosomal contents by all kinds of hydrolases (Hong et al., 2016). During the process of autophagosome biogenesis, Beclin1 plays a central role and governs the autophagic process by binding to phosphatidylinositol 3-kinase class III (PtdIns3KC3), which recruits additional autophagic proteins for autophagosome formation (Miki et al., 2016). ROCK1 phosphorylation of Beclin1 is the critical regulator for stress-induced autophagy (Gurkar et al., 2013). A reduction in ROCK1 is thought to diminish \( \beta \)-A\( \beta \) levels by enhancing lysosomal degradation of APP (Henderson et al., 2016).

To investigate the involvement of ROCK1 in the \( \beta \)-A\( \beta \) pathology diagnostic features for AD, the levels and location of ROCK1 in brain tissue from preclinical and clinical AD patients were examined. \( \beta \)-A\( \beta \) production and autophagosome formation following increases or decreases in ROCK1 levels were tested using cell culture methods. We showed that ROCK1 is deposited with highly aggregated \( \beta \)-A\( \beta \) in human brain tissue, and that activated ROCK1 inhibits autophagic \( \beta \)-A\( \beta \) clearance via interaction with Beclin1, increasing \( \beta \)-A\( \beta \) burden during AD progression.

### Materials and Methods

#### Pathological Cohort

The human ethics committee of the University of New South Wales approved this tissue study. Following institutional approvals, 10 \( \mu \)m formalin-fixed paraffin-embedded temporal cortex sections from 17 cases with different severities of AD pathology (female: male = 13:4, age = \( 87 \pm 9.5 \) years old), post mortem delay = \( 15 \pm 11 \) h, low severity, Braak stages 0–2 and not demented: intermediate severity and Braak stages 3–4: high severity, Braak stages 5–6 and dementia = \( 5:3:9 \) were obtained from the Sydney Brain Bank which collects brain tissue with informed consent from longitudinally followed research participants. Subjects were characterized according to recent criteria for the pathological diagnosis of AD. One of the cases with an intermediate severity had a diagnosis of AD for 3 years, while all those with a high probability of AD had dementia for between 5 and 17 years. Exclusion criteria were alternate neurodegenerative disorders or a dominant family history of neurodegenerative disorder.

#### Immunofluorescence

For immunofluorescence, the 10 \( \mu \)m formalin-fixed, paraffin-embedded sections underwent heat-induced antigen retrieval with Citrate Buffer p\( H \) 6 for 3 min, followed by formic acid pre-treatment for 3 min. Tissue sections were double-labeled with rabbit anti-ROCK1 (1:50, Abcam) and mouse monoclonal anti-human \( \beta \)1–42 (1:200, M0872, Dako, Glostrup, Denmark), and visualized with goat anti-rabbit Alexa Fluor 488 (1:500, A-11008, Life Technologies) and goat anti-mouse Alexa Fluor® 594 (1:500, A-11005, Life Technologies), respectively. Sections were coverslipped with Vectashield HardSet Antifade Mounting Medium with DAPI (H-1500, Vector Laboratories, Burlingame, CA, USA) and examined on confocal microscope (Nikon Eclipse E400).

#### Quantitative Analysis of \( \beta \)-A\( \beta \) and ROCK1 Colocalization

For quantification, 10 images were made for each case where plaques were present. All diffuse and cored plaques on each image was identified using the \( \beta \)-A\( \beta \)1–42 immunofluorescence, and the proportion that had ROCK1 co-localization recorded separately for both diffuse and core plaques. In total, an
average of 40 ± 17 plaques were examined per case, with 66% on average being diffuse and 36% being cored. Multivariate statistics were performed in SPSS (IBM, v23) to assess differences between the percentages of plaques colocalizing ROCK1 immunoreactivity and the severity of cortical plaques observed, as assessed by the CERAD score (0 = none, 1 = mild or 1–5/image, 2 = moderate or 6–15/image and 3 = severe or more than 15/image), as well as to case diagnosis based on pathological load of different plaque types and neurofibrillary tangles (control, preclinical AD and AD).

**Cell Lines and Cell Culture**

HEK293 cells stably transfected with human APP695 harboring the “Swedish” mutation (HEK293 APP695sw) and SH-SY5Y human neuroblastoma were maintained in Eagle’s minimal essential media or DMEM (Gibco), respectively, with 10% human neuroblastoma were maintained in Eagle’s minimal media or DMEM (Gibco), respectively, with 10% fetal bovine serum, and 1% penicillin/streptomycin. Cells were seeded at 100,000 cells/cm² density in 6-well dishes that were coated with 100 µg/ml poly-lysine. On day 2 post plating, cells were transfected with indicated lentivirus with a multiplicity of infection of 1. For all studies, cells were treated with drugs at 72 h post-transduction in conditioned media for 16 h. For RNAi knockdown of ROCK1, cells were harvested 96 h post-transduction. For transfections or transfections, equivalent amounts of cells were plated, and transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. At 72 h post-transfection, cells were treated as indicated and then processed for western blot analysis or fluorescence imaging.

**Cell Proliferation Assay**

Cell proliferation was measured by the CCK-8 Kit (Beyotime) according to the manufacturer’s instructions. Cells in 100 µl media were treated with 10 µl CCK-8 reagent at 37°C for 2 h, followed by measuring the absorbance at 450 nm on a microplate reader.

**Plasmid Construct, RNA Interface and Transfection**

ROCK1 plasmid (pCAG-myc-ROCK1myc-727 ∆3, ROCK1 CA) was constructed as previously reported (Ishizaki et al., 1997). The siRNA sequence against ROCK1 (sense 5′-GGCAGAGGAAUAUAATT-3′; antisense 5′-UUUAUUUCUUUCUCUGCTT-3′) and scrambled siRNA was synthesized by GenePharma (Shanghai, China). Cells were transfected with ROCK1 plasmid, ROCK1 siRNA or scrambled siRNA using Lipofectamine 2000 reagent according to the manufacturer’s instructions. At 72 h post-transfection, cells and supernatant were harvested and then processed for western blot analysis.

**Aβ Measurements**

For all cells, conditioned media were used for 48 h, and then the cells and media collected separately for biochemical analyses. Aβ40 following the manufacturer’s instructions. Plates were read at 450 nm on a Synergy MX plate reader (BioTek, Winooski, VT, USA).

**Immunoblotting**

Cells were lysed with 1% RIPA Lysis Buffer (Beyotime, China). Cell lysate was subjected to a 13,000 rpm spin to remove nuclei and debris. Cleared lysate was used for the indicated biochemical assay. Protein concentrations were determined using the Enhanced BCA Protein Assay Reagent (Beyotime). Equal amounts of cell lysate were loaded onto SDS-PAGE gels and then transferred to PVDF membranes. Membranes were blocked with 5% fat-free dry milk in Tris buffered saline (TBS), containing 0.05% Tween-20, and incubated with primary antibodies. Protein bands were detected by horseradish peroxidase-conjugated species-specific secondary antibodies. Actin was used as loading control. Images were captured using an Odyssey Image Station (LI-COR), and band intensities were quantified using Scion Image.

**mCherry-GFP-LC3B Assay**

In order to evaluate the effects of ROCK1 plasmid on GFP–LC3B puncta formation, SH-SY5Y cells were plated on poly-lysine-coated 96-well plates and transduced with adenovirus expressing mCherry-GFP-LC3B fusion protein. After 24 h and 48 h, cell images were obtained by EVOS fl Auto (Life, USA).

**Co-Immunoprecipitation**

Co-immunoprecipitation (CoIP) was performed as previously described (Rijal Upadhaya et al., 2014). HEK293 cells in 60-mm dishes were co-transfected with pCAG-myc-ROCK1myc-727 ∆3 plasmid. Forty eight hours later, the cells were lysed with 1% RIPA Lysis Buffer (Beyotime). After clarification by centrifugation at 4°C for 30 min at 12,000 rpm, 500 µl cell lysates were incubated with 20 µl of protein A + G agarose beads (Beyotime, China) for 4 h with gentle rotation at 4°C. The beads were washed four times with the cell lysis buffer and precipitates were eluted with 2× SDS-PAGE sample buffer, and then analyzed by western blot for anti-Myc and anti-Beclin1 immunoreactivity, respectively.

**Primary Neuron Culture, Transfection and Immunofluorescence**

Primary cortical neurons were prepared from E16 to E18 days of Sprague-Dawley rat brain tissues. Briefly, cerebral cortex was removed aseptically, and then digested and dispersed into single cells; then neurons were re-suspended in neuro-basal medium with 2% B27 supplement (Invitrogen), 2 mM glutamine and 1% penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA) and then seeded at 1.25 × 10⁵ cells per cm² on 12-well plates (Corning Inc., Midland, NC, USA) coated with 100 µg/ml poly-l-lysine and incubated in humidified atmosphere with 5% CO₂ at 37°C. Transfection using Lipofectamine 2000 (Invitrogen) was carried out on acutely dissociated neurons before plating, and 4 h later, the whole medium was replaced with NB/B27 and immunofluorescence experiment was performed after 48 h transfection.
For immunofluorescence, primary neurons were cultured on a cover glass and fixed with 4% paraformaldehyde in PBS for 10 min at room temperature. Permeabilization was performed in PBS with 0.3% Triton X-100 for 10 min at room temperature. After blocking for 30 min with 5% normal donkey serum, neurons were incubated with rabbit anti-LC3 (1:100, CST) antibody or mouse anti-ROCK1 (1:500, Abcam) antibody overnight at 4°C. After washing three times with 0.1 M PBS, the sections were incubated with AlexaFluor 488-conjugated donkey anti-rabbit or anti-mouse IgG secondary antibodies (Invitrogen), respectively, and the sections were visualized with a confocal microscope (FV-1000).

### Immunohistochemistry and Histology

APP/PS1 mice were provided by Model Animal Research Center of Nanjing University. APP/PS1 mice have been intensively characterized for Aβ plaques load and AD behavioral phenotypes. In this experiment, 10-month-old APP/PS1 transgenic mice and age-matched C57BL/6J were used. Behavioral phenotypes. In this experiment, 10-month-old APP/PS1 mice were provided by Model Animal Research Center of Nanjing University. APP/PS1 mice have been intensively characterized for Aβ plaques load and AD behavioral phenotypes. In this experiment, 10-month-old APP/PS1 transgenic mice and age-matched C57BL/6J were used.

#### Antibodies and Reagents

Mouse anti-ROCK1 antibody (Abcam, 1:500 dilution), rabbit anti-Beclin1 (Novus, 1:10,000), rabbit anti-APP-CTF (Sigma-Aldrich, 1:5000), anti-mouse sAPPα (IBL, 1:50), anti-mouse myc (Abcam, 1:1000), anti-rabbit LC3 (Cell Signaling, 1:100) and mouse anti-β-actin (Sigma-Aldrich, 1:1000) were used. Loading controls (β-actin) were used for Western blot standardization. Lipofectamine 2000 was sourced from Invitrogen. 3-methyladenine (3-MA) was purchased from Sigma Aldrich (St. Louis, MO, USA) and 3-MA was dissolved in double distilled water and titrated to 1 mM.

#### Statistical Analysis of the Cell Culture Experiments

Data are reported as mean ± SEM. Comparisons between experimental groups were analyzed by Student’s t-test or ANOVA as appropriate, with p < 0.05 considered as significant.

### RESULTS

#### ROCK1 is Associated with Aβ Plaques in the Brains of AD Patients

To determine whether Aβ associates with ROCK1 in the brains of patients with AD, co-localization studies were performed using specific antibodies in healthy aged controls (n = 5 aged 89 ± 4 years, Braak neuritic stages 0–2), preclinical AD (n = 4 aged 85 ± 3 years, Braak neuritic stages 3–4) and clinical end-stage AD (n = 8 aged 86 ± 4 years, Braak neuritic stages 5–6). Consistent with this finding, ROCK1 immunoreactivity was identified in more cored than diffuse plaques (Figure 1). Quantitation showed that the majority of cored plaques contained ROCK1 immunoreactivity, and that colocalization increased with increasing severity of cortical Aβ deposition as assessed by CERAD plaque score (Figure 1j, Wilks’ Lambda p < 0.0001 covarying for age and brain size, post hoc Bonferroni p = < 0.002). Nearly half of all Aβ plaques in preclinical AD contained ROCK1 immunoreactivity, with significantly higher numbers of ROCK1-immunopositive Aβ plaques found in AD patients (Figure 1k, Wilks’ Lambda p = 0.03 covarying for age and brain size, post hoc Bonferroni p = 0.003 for AD diagnosis). These results demonstrate a close relationship between ROCK1 localization and pathological Aβ plaque in both preclinical and clinical AD.

#### ROCK1 Regulates Aβ Secretion

To further explore the effects of ROCK1 cleavage on the production of Aβ, we constructed a plasmid expressing this constitutively active ROCK1 fragment (ROCK1 CA), as previously reported (Ishizaki et al., 1997). In HEK 293T cells stably transfected with the APP695 Swedish mutation (APPsw), ROCK1 levels were manipulated by transfection with ROCK1 CA plasmid, ROCK1 siRNA or scrambled siRNA. Forty eight hours after transfections, the levels of secreted Aβ40 in the cell culture medium were measured by ELISA. As shown in Figure 2, secreted Aβ40 levels were increased by 80% compared to the control after depletion of ROCK1 (Figures 2a,b), which is consistent with a recent study. In contrast, secreted Aβ40 levels were decreased following ROCK1 CA over-expression in HEK293T APPsw cells (Figures 2c,d). The Aβ42 level was too low to be detected by ELISA. ROCK1 CA plasmid transfection did not change cell proliferation (Figure 2e). These results confirm that ROCK1 influences Aβ secretion.

#### ROCK1 Modulates APP Shedding

Given that there is an established relationship between ROCK1 and Aβ secretion, we next investigated the effects of ROCK1 on APP cleavage. After transfection of ROCK1-targeted siRNA or ROCK1 CA plasmid to HEK293T APPsw cells, cells were harvested 48 h later and lysates were analyzed. The holo-APP and sAPPα were examined by Western Blot with the mAb 6E10, specific for residues 1–17 of the Aβ sequence (Figure 3a). Electrophoresis revealed no significant difference of full-length APP (Figure 3c), however the amount of sAPPα was higher after ROCK1 depletion (Figure 3d). In cells with increased ROCK1 CA levels, sAPPα was significantly decreased (Figure 3d). These results confirm that ROCK1 modulates the metabolism of APP. To further explore the interaction between ROCK1 and APP/Aβ, we performed normal HEK293T cell culture with Aβ40 treatment or APP695 plasmid transfection. Addition of Aβ40 or APP695 over-expression promoted endogenous ROCK1 expression in normal HEK293T cells (Figures 3b,e).
Identification of ROCK1 as an Enhancer of Beclin1 Dependent Autophagy

In further experiments, we explored the mechanism of ROCK1 as an enhancer of Beclin1 dependent autophagy. When ROCK1 was depleted, the expression of Beclin1 was decreased, and when ROCK1 CA was over-expressed by plasmid transfection, the level of Beclin1 was also increased. To determine whether autophagy is involved in the mechanism...
FIGURE 2 | ROCK1 levels modulate Aβ secretion. (A,C) Effects of knocking down ROCK1 levels (A) and increasing constitutively activated ROCK1 (ROCK1 CA) levels (C) on secreted Aβ. HEK293 cells were transfected with ROCK1 siRNA (siROCK1), scramble siRNA (siCON), ROCK1 CA plasmid and pcDNA (Con) and 48 h post-transfection secreted Aβ40 was measured by ELISA. (B,D) Representative immunoblot confirms ROCK1 knockdown (B) and increase (D). (E) Cell proliferation assay following ROCK1 CA plasmid transfection. Data are presented as Mean ± SEM. Graphs represent % of control groups, n = 10; students’ t test, ***p < 0.01.

APP/PS1 Mice have Increased ROCK1 and Neuronal Autophagosome Accumulation
After confirming the relationship between ROCK1 and autophagosome formation in vitro, we next assessed whether ROCK1 and autophagosome proteins are upregulated with Aβ in vivo by conducting immunofluorescence and IHC staining of brain sections from 10 months old APP/PS1 transgenic C57BL/6 mice. Our data showed that ROCK1 was increased significantly with neuronal autophagosomes accumulation (Figures 5A,C) and that Beclin1 was decreased in the AD mouse model (Figures 5B,D). These observations suggested that autophagy was impaired in neurons and increased ROCK1 inhibited Aβ secretion, resulting in intracellular Aβ accumulation and neurotoxicity. Taken together, these data demonstrated the same associations between ROCK1, intracellular Aβ and autophagosomes accumulation as we identified in our in vitro experiments.

DISCUSSION
The critical events that trigger or cause increased Aβ levels and post-translational modifications that increase Aβ insolubility are still under debate. However, modulation of the production, metabolism and fibrilization of the protein are key pathogenic aspects. Our results show that ROCK1 levels regulate Aβ clearance by modulating the autophagy pathway via an interaction with its substrate, Beclin1, that initiates autophagosome formation that then accumulate...
intracellularly. This is consistent with previous studies showing that ROCK1 regulates autophagosome formation (Gurkar et al., 2013), that autophagosomes accumulate in AD and that ROCK1 inhibition reduces Aβ levels in brain (Nixon and Yang, 2011). Our data also show that ROCK1 collocates with fibrillized Aβ. It has recently been shown that different post-translational modifications of Aβ occur in different types of plaques (Rijal Upadhaya et al., 2014). The cases in this study have been previously analyzed using Western blotting for ROCK1 with no reduction in membrane associated SDS-soluble ROCK1 protein levels by end-stage AD (Wang et al., 2016). Taken together, our data indicate that ROCK1 may be involved in Aβ modification.

Phosphorylation of Aβ at serine 8 at the cell surface has recently been identified to dramatically increase the rate and amount of Aβ oligomerization and amyloid fibril formation (Rezaei-Ghaleh et al., 2016). In fact, AD patients are distinguished from those without clinical AD by selectively accumulating this phosphorylated form of Aβ (Rijal Upadhaya et al., 2014). The kinases that are involved in phosphorylating Aβ are poorly understood, but are thought to be of the AGC kinase family of serine-threonine kinases (Rezaei-Ghaleh et al., 2016), which includes ROCK1. Unlike ROCK2, ROCK1 interacts with a number of proteins in the plasma membrane (Stroeken et al., 2006) and we show that ROCK1 co-localizes with highly fibrillized Aβ in human brain. The localization and association of ROCK1-associated Aβ with clinical AD mirrors the data observed for serine 8 phosphorylated Aβ (Rijal Upadhaya et al., 2014) and suggests that ROCK1 may be the kinase involved in this disease-specific Aβ phosphorylation.

We provide further evidence that ROCK1 has a role in the plasma membrane in its influence on APP shedding. APP shedding is directly mediated by α- and β-secretase generating either non-amyloidogenic (sAPPα) or amyloidogenic fragments (Tang, 2005). Our data show that ROCK1 activation enhances the amyloidogenic pathway, consistent with recent data (Henderson et al., 2016). However, we demonstrate that ROCK1 decreased sAPPα shedding in cultured cells, but also reduced rather than increased Aβ secretion from the cells, suggesting that ROCK1 may also play a role in Aβ secretion at the plasma membrane (potentially associated with the aberrant phosphorylation of Aβ, see above). Together these results are also consistent with ROCK1 activation increasing intracellular Aβ.

We show that activated ROCK1 inhibits the autophagic clearance of Aβ via its interaction with Beclin1, increasing Aβ burden during AD progression. Autophagy is a critical clearance system for cellular toxic protein aggregates and it is crucial for the physiological regulation of normal cell function, which can be induced by extracellular and intracellular signals, including oxidative stress, starvation and endoplasmic reticulum stress (Wang and Mao, 2014). In the brain, the complex axonal and dendritic structures are highly dependent on efficient autophagic turnover (Wong and Holzbaur, 2015; Hong et al., 2016). In AD, autophagy is upregulated at early disease stages, as evidenced by swollen endosomes and the accumulation of autophagosomes (Wong and Holzbaur, 2015). At the transcriptional level, autophagy-activating factors are also upregulated in AD (jiang et al., 2013). ROCK1 phosphorylation of Beclin1 is known to be the critical regulator for stress-induced autophagy (Gurkar et al., 2013). We confirm that Beclin1 is a
substrate of ROCK1 and that the interaction of ROCK1 and Beclin1 results in the inhibition of autophagic Aβ clearance. It is well known that Beclin1 is a critical regulator of autophagy and several lines of investigation have demonstrated that autophagy plays an important role in Aβ clearance (also known as “autophagic Aβ clearance”; Wirawan et al., 2012). Although ROCK1 phosphorylation of Beclin1 activates autophagosome production, our data show that these organelles accumulate intracellularly with enhanced intracellular Aβ and a reduction in secreted Aβ. This is consistent with previous reports showing that autophagosome maturation to autolysosomes is the main problem with autophagy in AD and results in accumulating intracellular Aβ (Nixon and Yang, 2011).
Overall our data suggest a role for ROCK1 in regulating Aβ production, secretion and post-translational modification at the plasma membrane, as well as its important role in intracellular autophagosome induction. The location of ROCK1 to the plasma membrane (Stroeken et al., 2006), and also in extracellular plaques (as shown in this study), makes this kinase potentially more easily targetable and relevant for therapeutic manipulations than others. If as suggested, Aβ phosphorylation at serine 8 enhances plaque maturation to progress presymptomatic pathology to symptomatic AD (Rijal Upadhaya et al., 2014), then inhibition of ROCK1 and/or Aβ dephosphorylating enzymes, may provide the most relevant treatments. Taken together, our findings outline a critical role of ROCK1 in the progression of Aβ pathology, highlighting its potential as a therapeutic target.

**AUTHOR CONTRIBUTIONS**

Y-BH and YZ performed most experiments, collected and analyzed data, and wrote the manuscript. YH and GFL performed pathological experiments. GW, R-JR, S-DC and GMH participated in the design of the study. Manuscript was written by
Y-BH and YH, and critically reviewed by GW, R-JR, Y-FZ, S-DC and GMH. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

This study was supported by the National Basic Research Development Program of China (Nos. 2010CB945200, 2011CB504104), the National Natural Science Foundation of China (Nos. 81001426, 81171027, 81200842, 91332107), Shanghai Pujiang Program (No. 15PJ1405400) and the National Health and Medical Research Council of Australia (program grant #1037746 and senior principal research fellowship grant #1079679). Human brain tissue was received from the Sydney Brain Bank at Neuroscience Research Australia that is supported by the University of New South Wales and Neuroscience Research Australia.

REFERENCES

Chang, J., Xie, M., Shah, V. R., Schneider, M. D., Entman, M. L., Wei, L., et al. (2006). Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc. Natl. Acad. Sci. U. S. A. 103, 14495–14500. doi: 10.1073/pnas.0601911103

Chong, C. M., Ai, N., and Lee, S. M. (2016). ROCK in CNS: different roles of isoforms and therapeutic target for neurodegenerative disorders. Curr. Drug Targets 17. doi: 10.2174/13894501176661041123825 [Epub ahead of print]

Christensen, D. Z., Kraus, S. L., Flohr, A., Cotol, M. C., Wirths, O., and Bayer, T. A. (2008). Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 116, 647–655. doi: 10.1007/s00401-008-0451-6.

Dlugos, C. A., and Pentney, R. J. (2002). Quantitative immunocytochemistry of GABA and synaptophysin in the cerebellar cortex of old ethanol-fed rats. Alcohol. Clin. Exp. Res. 26, 1728–1733. doi: 10.1111/j.1530-0272.2002.tb02477.x

Gurkar, A. U., Chu, A., Raj, L., Bouley, R., Lee, S. H., Kim, Y. B., et al. (2013). Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat. Commun. 4:2189. doi: 10.1038/ncomms3189

Henderson, B. W., Gentry, E. G., Rush, T., Troncoso, J. C., Thambisetty, M., Montine, T. J., et al. (2016). Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer’s disease and ROCK1 depletion reduces amyloid-β levels in brain. J. Neurosci. 36, 523–531. doi: 10.1177/jnsc.13668

Herskovitz, J. H., Feng, Y., Matthesyes, A. L., Hales, C. M., Higginbothom, L. A., Duong, D. M., et al. (2013). Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer’s disease mouse model. J. Neurosci. 33, 19086–19098. doi: 10.1523/JNEUROSCI.2508-13.2013

Hong, C. J., Park, H., and Yu, S. W. (2016). Autophagy for the quality control of adult hippocampal neural stem cells. Brain Res. 1649, 166–172. doi: 10.1016/j.brainres.2016.02.048

Ishizaki, T., Naito, M., Fujisawa, K., Maekawa, M., Watanabe, N., Saito, Y., et al. (1997). p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 404, 118–124. doi: 10.1016/s0014-5793(97)01075-5

Jacobs, M., Hayakawa, K., Swenson, L., Bellon, S., Fleming, M., Taslimi, P., et al. (2006). The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J. Biol. Chem. 281, 260–268. doi: 10.1074/jbc.M508847200

Jiang, W., Zhang, Y., Mori, F., Utsumi, J., Sasaki, H., Kakita, A., et al. (2016). Alteration of upstream autophagy-related proteins (ULK1, ULK2, Beclin1, VPS34 and AMBRA1) in lewy body disease. Brain Pathol. 26, 359–370. doi: 10.1111/bpa.12297

Nixon, R. A., and Yang, D. S. (2011). Autophagy failure in Alzheimer’s disease—locating the primary defect. Neurobiol. Dis. 43, 38–45. doi: 10.1016/j.nbd.2011.01.021

Rezaei-Ghaleh, N., Amininasab, M., Kumar, S., Walter, J., and Zweckstetter, M. (2016). Phosphorylation modifies the molecular stability of beta-amyloid deposits. Nat. Commun. 7:11359. doi: 10.1038/ncomms11359

Rijal Upadhyaya, A., Kosterin, I., Kumar, S., von Arnim, C. A., Yamaguchi, H., Fändrich, M., et al. (2014). Biochemical stages of amyloid-beta peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease. Brain 137, 887–903. doi: 10.1093/brain/awt362

Salminen, A., Suuronen, T., and Kaarniranta, K. (2008). ROCK, PKA and Toll of synapses in Alzheimer’s disease. Biochem. Biophys. Res. Commun. 371, 587–590. doi: 10.1016/j.bbrc.2008.04.148

Shu, J., Wu, X., Surma, M., Vemula, S., Zhang, L., Yang, Y., et al. (2013). Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis. 4:e843. doi: 10.1038/cddis.2013.10

Stroeken, P. J., Alvarez, B., Van Rheenen, J., Wijnands, Y. M., Geerts, D., Jalink, K., et al. (2006). Integral cytoplasmic domain-associated-protein-1 (ICAP-1) interacts with the ROCK-I kinase at the plasma membrane. J. Cell. Physiol. 208, 620–628. doi: 10.1002/jcp.20699

Sugrue, M. L., Vella, K. R., Morales, C., Lopez, M. E., and Hollenberg, A. N. (2010). The thyrotropin-releasing hormone gene is regulated by thyroid hormone at the level of transcription in vivo. Endocrinology 151, 793–801. doi: 10.1210/en.2009-0976

Swanger, S. A., Matthesyes, A. L., Gentry, E. G., and Herskowitz, J. H. (2015). ROCK1 and ROCK2 inhibition alters dendritic spine morphology in hippocampal neurons. Cell. Logist. 5:e113266. doi: 10.1016/j.celrep.2015.11.33266

Tang, B. L. (2005). Alzheimer’s disease: channeling APP to non-amyloidogenic processing. Biochem. Biophys. Res. Commun. 331, 375–378. doi: 10.1016/j.bbrc.2005.03.074

Wang, G., Huang, Y., Wang, L. L., Zhang, Y. F., Xu, J., Zhou, Y., et al. (2016). MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease. Sci. Rep. 6:26697. doi: 10.1038/srep26697

Wang, G., and Mao, Z. (2014). Chaperone-mediated autophagy: roles in neurodegeneration. Transl. Neurodegener. 3:20. doi: 10.1186/2047-9158-3-20

Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., et al. (2001). A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212–216. doi: 10.1038/35102591

Wirawan, E., Lippens, S., VandenBergh, T., Romagnoli, A., Fimia, G. M., Picentini, M., et al. (2012). Beclin1: a role in membrane dynamics and beyond. Autophagy 8, 6–17. doi: 10.4161/auto.8.1.16645
Wong, Y. C., and Holzbaur, E. L. (2015). Autophagosome dynamics in neurodegeneration at a glance. J. Cell Sci. 128, 1259–1267. doi: 10.1242/jcs. 161216

Yang, H., Wittnam, J. L., Zubarev, R. A., and Bayer, T. A. (2013). Shotgun brain proteomics reveals early molecular signature in presymptomatic mouse model of Alzheimer’s disease. J. Alzheimers Dis. 37, 297–308. doi: 10.3233/JAD-130476

Zhang, Z., Miah, M., Culbreth, M., and Aschner, M. (2016). Autophagy in neurodegenerative diseases and metal neurotoxicity. Neurochem. Res. 41, 409–422. doi: 10.1007/s11064-016-1844-x

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Hu, Zou, Huang, Lourenco, Chen, Halliday, Wang and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.